Induction of remission in a patient with metastatic breast cancer refractory to trastuzumab and chemotherapy following treatment with gefitinib ('Iressa', ZD1839)

Anti-Cancer Drugs

Volumn 15, Issue 3, 2004, Pages 235-238

  Schneeweiss, Andreas ^a   Kolay, Sema ^a   Aulmann, Sebastian ^a   Von Minckwitz, Gunter ^b   Torode, Julie ^c   Koehler, Maria ^c   Bastert, Gunther ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Universitaetsklinikum   (Germany)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Gefitinib; Metastatic breast cancer; Trastuzumab

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; GEFITINIB; GROWTH FACTOR RECEPTOR; NAVELBINE; PACLITAXEL; PAMIDRONIC ACID; TRASTUZUMAB;

ADULT; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER REGRESSION; CANCER SURVIVAL; CASE REPORT; DIARRHEA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; RASH;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPH NODES; MIDDLE AGED; QUINAZOLINES; RECEPTORS, GROWTH FACTOR; REMISSION INDUCTION; SKIN NEOPLASMS;

EID: 1842479986     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200403000-00007     Document Type: Article

References (17)

1. Stockler M, Wilcken NR, Ghersi D, Simes RJ. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev 2000; 26:151-168.
2. Normanno N, Campiglio M, De Luca A, Somenzi G, Maiello M, Ciardiello F, et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 2002; 13:65-72.
3. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6:2053-2063.
4. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fl, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792.
5. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996; 16:5276-5287.
6. Eiermann W. International Herceptin Study Group. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data. Ann Oncol 2001; 12(suppl 1):S57-S62.
7. Robertson JFR, Gutteridge E, Cheung KL, Owers R, Koehler M, Hamilton L. A Phase II study of ZD1839 ('Iressa') in tamoxifen-resistant ER-positive and endocrine insensitive (ER-negative) breast cancer. Breast Cancer Res Treat 2002; 76:S96 (abstr 357).
8. Albain KS, Elledge R, Gradishar WJ, Hayes DF, Rowinsky E, Hudis C, et al. Open-label, phase II, multicenter trial of ZD1839 ('Iressa') in patients with advanced breast cancer. Breast Cancer Res Treat 2002; 76:S1 (abstr 20).
9. Qi CF, Liscia DS, Normanno N, Merlo G, Johnson GR, Gullick WJ, et al. Expression of transforming growth factor alpha, amphiregulin and cripto-1 in human breast carcinomas. Br J Cancer 1994; 69:903-910.
10. Normanno N, Kim N, Wen D, Smith K, Harris AL, Plowman G, et al. Expression of messenger RNA for amphiregulin, heregulin, and cripto-1, three new members of the epidermal growth factor family, in human breast carcinomas. Breast Cancer Res Treat 1995; 35:293-297.
11. Panico L, D'Antonio A, Salvatore G, Mezza E, Tortora G, De Laurentiis M, et al. Differential immunohistochemical detection of transforming growth factor alpha, amphiregulin and CRIPTO in human normal and malignant breast tissues. Int J Cancer 1996; 65:51-56.
12. Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 ('Iressa') inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001; 61: 7184-7188.
13. Lieberman FS, Cloughesy T, Deangelis L, Fine H, Fink K, Junck L, et al. For the North American Brain Tumor Consortium. Phase I-II study of ZD-1839 for recurrent malignant gliomas and meningiomas progressing after radiation therapy. Proc Am Soc Clin Oncol 2003; 22:105 (abstr 421).
14. Peery TS, Reardon DA, Quinn J, Ochs J, Wikstrand C, Stenzel TT, et al. Phase II trial of ZD1839 for patients with first relapse glioblastoma. Proc Am Soc Clin Oncol 2003; 22:99 (abstr 396).
15. Heimberger AB, Learn CA, Archer GE, McLendon RE, Chewning TA, Tuck FL, et al. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002; 8:3496-3502.
16. Knuti KA, Wharton RH, Wharton KL, Chabner BA, Lynch Jr TJ, Penson RT. Living as a cancer surpriser: a doctor tells his story. Oncologist 2003; 8:108-122.
17. Villano JL, Mauer AM, Vokes EE. A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain. Ann Oncol 2003; 14:656-658.